Influence of the corticotropin releasing hormone (CRH) on the brain-blood barrier permeability in cerebral ischemia in rats.
The increase in the blood-brain barrier (BBB) permeability and a developing cerebral oedema due to the ischemic infarction appear a few hours, and intensify during a few days, after closing the carotid arteries. It fails to be clear, however, what causes the increase in the microvessels damage, and whether the damage is a secondary result of the vasoactive substances released by the neurones and glia cells damaged by the ischemia. CRH, which plays an essential role in integrative the nervous, endocrine, and immunological systems, has a positive effect on the decrease in the permeability of the BBB damaged by various physical and chemical factors. Therefore, the examination of the CRH role in the cerebral ischemia may prove useful for explaining the processes taking place in the foci of the cerebral infarction and their environment. The experiment was carried out on rats which, 20 minutes before closing of both internal carotid arteries, was administered 10 microg CRH to cerebrospinal fluid via cisterna magna of the brain. The BBB permeability was measured 30 minutes, 3 hours, 3 days, and 7 days after closing the arteries. The experiment has shown the CRH protective effect on the BBB and its consequent effect on the decrease in the BBB permeability which appears in the 3 hours after closing the arteries (p<0.05), and is high significant during the chronic phase of the cerebral ischemia (p<0.03). It can be thus concluded that CRH, by affecting directly the endothelium of the cerebral vessels, decreases the endothelial damage in the acute phase of the ischemia. The decrease is noted to be more significant in the chronic phase of the ischemia; such an effect can be attributed to CRH stimulating the hypothalamic-adrenal axis, and to the secondary activation of the mechanisms decreasing the BBB permeability.
Hendryk
S
S
Department of Neurosurgery and Neurotraumatology in Bytom, Silesian Medical University in Katowice, Poland. neusurg@infomed.slam.katowice.pl
Jedrzejowska-Szypulka
H
H
Jośko
J
J
Jarzab
B
B
Döhler
K D
KD
D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects*; D002545:Brain Ischemia / Q000139:chemically induced / Q000503:physiopathology*; D002404:Catheterization; D002946:Cisterna Magna / Q000502:physiology; D004396:Coloring Agents; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology*; D005070:Evans Blue; D018691:Excitatory Amino Acid Antagonists; D007649:Ketamine; D008297:Male; D051381:Rats; D017208:Rats, Wistar
D004396:Coloring Agents; D018691:Excitatory Amino Acid Antagonists; D005070:Evans Blue; D007649:Ketamine; D003346:Corticotropin-Releasing Hormone